Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based clinical stage biopharmaceutical company developing donor-derived, cell-based allogeneic immunotherapies for cancers. This news page aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how CytoMed’s gamma delta T cell and iPSC-derived platforms progress from research into clinical application.
According to its public communications, CytoMed is advancing a Phase I CAR gamma delta T cell trial in Singapore (the ANGELICA Trial), supporting a Phase II Investigator-Initiated Trial in India, and preparing a first-in-human trial in Malaysia for unmodified allogeneic γδ T cells in collaboration with Universiti Malaya. News items frequently cover milestones such as completion of dose levels in the ANGELICA Trial, memoranda of understanding with hospital partners, and publications of collaborative research with institutions like The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia.
Investors and observers can also find updates on CytoMed’s corporate developments, including the build-out of its cord blood-derived platform under subsidiary LongevityBank, the acquisition of a licensed cord blood bank in Malaysia, and non-dilutive investment into LongevityBank. Additional announcements may describe asset acquisitions related to T cell technologies, at-the-market equity programs, and changes in significant shareholdings.
For those tracking GDTC, this news feed provides a centralized view of CytoMed’s progress in oncology-focused cell therapies, its expansion into cord blood-derived and regenerative applications, and its evolving strategy in Southeast Asia, India and China. Regularly reviewing these updates can help readers understand how the company’s clinical, scientific and corporate activities develop over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CytoMed Therapeutics Limited (Nasdaq: GDTC) has successfully completed its initial public offering (IPO), raising a total of US$9,649,476 through the sale of 2,412,369 ordinary shares priced at US$4.00 each. The IPO marks a significant step for the pre-clinical biopharmaceutical company, which specializes in developing innovative cell-based immunotherapies for cancer treatment. Shares started trading on the Nasdaq Capital Market on April 14, 2023. Underwriters also have a 45-day option to purchase an additional 361,855 shares. The offering was facilitated by The Benchmark Company, LLC and Axiom Capital Management, Inc. Regulatory approvals were secured with the SEC declaring the corresponding registration effective on March 31, 2023.
CytoMed Therapeutics Limited has announced the pricing of its initial public offering (IPO) at US$4.00 per share, aiming to raise US$9.65 million in gross proceeds. The IPO includes 2,412,369 ordinary shares, with an option for underwriters to purchase an additional 361,855 shares for over-allotments. Trading on the Nasdaq Capital Market under the ticker symbol GDTC is set to begin on April 14, 2023, with the offering expected to close on April 18, 2023. Proceeds will support the clinical development of multiple product candidates and R&D activities. The offering follows SEC approval of the registration statement on March 31, 2023.